FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038798082> ?p ?o ?g. }

• W3038798082 endingPage "828" @default.
• W3038798082 startingPage "811" @default.
• W3038798082 abstract "Background & AimsGemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as novel biomarkers to predict the gemcitabine response and the therapeutic targets to attenuate chemoresistance in PDAC cells.MethodsGenome-wide RNA interference screening was conducted to identify genes that regulated gemcitabine chemoresistance. A cell proliferation assay and a tumor formation assay were conducted to study the role of lethal giant larvae homolog 1 (LLGL1) in gemcitabine chemoresistance. Levels of LLGL1 and its regulating targets were measured by immunohistochemical staining in tumor tissues obtained from patients who received gemcitabine as a single therapeutic agent. A gene-expression microarray was conducted to identify the targets regulated by LLGL1.ResultsSilencing of LLGL1 markedly reduced the gemcitabine chemosensitivity in PDAC cells. Patients had significantly shorter survival (6 months) if they bore tumors expressing low LLGL1 level than tumors with high LLGL1 level (20 months) (hazard ratio, 0.1567; 95% CI, 0.05966–0.4117). Loss of LLGL1 promoted cytokine receptor oncostatin M receptor (OSMR) expression in PDAC cells that led to gemcitabine resistance, while knockdown of OSMR effectively rescued the chemoresistance phenotype. The LLGL1-OSMR regulatory pathway showed great clinical importance because low LLGL1 and high OSMR expressions were observed frequently in PDAC tissues. Silencing of LLGL1 induced phosphorylation of extracellular signal-regulated kinase 2 and specificity protein 1 (Sp1), promoted Sp1 (pThr453) binding at the OSMR promoter, and enhanced OSMR transcription.ConclusionsLLGL1 possessed a tumor-suppressor role as an inhibitor of chemoresistance by regulating OSMR–extracellular signal-regulated kinase 2/Sp1 signaling. The data sets generated and analyzed during the current study are available in the Gene Expression Omnibus repository (ID: GSE64681). Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as novel biomarkers to predict the gemcitabine response and the therapeutic targets to attenuate chemoresistance in PDAC cells. Genome-wide RNA interference screening was conducted to identify genes that regulated gemcitabine chemoresistance. A cell proliferation assay and a tumor formation assay were conducted to study the role of lethal giant larvae homolog 1 (LLGL1) in gemcitabine chemoresistance. Levels of LLGL1 and its regulating targets were measured by immunohistochemical staining in tumor tissues obtained from patients who received gemcitabine as a single therapeutic agent. A gene-expression microarray was conducted to identify the targets regulated by LLGL1. Silencing of LLGL1 markedly reduced the gemcitabine chemosensitivity in PDAC cells. Patients had significantly shorter survival (6 months) if they bore tumors expressing low LLGL1 level than tumors with high LLGL1 level (20 months) (hazard ratio, 0.1567; 95% CI, 0.05966–0.4117). Loss of LLGL1 promoted cytokine receptor oncostatin M receptor (OSMR) expression in PDAC cells that led to gemcitabine resistance, while knockdown of OSMR effectively rescued the chemoresistance phenotype. The LLGL1-OSMR regulatory pathway showed great clinical importance because low LLGL1 and high OSMR expressions were observed frequently in PDAC tissues. Silencing of LLGL1 induced phosphorylation of extracellular signal-regulated kinase 2 and specificity protein 1 (Sp1), promoted Sp1 (pThr453) binding at the OSMR promoter, and enhanced OSMR transcription. LLGL1 possessed a tumor-suppressor role as an inhibitor of chemoresistance by regulating OSMR–extracellular signal-regulated kinase 2/Sp1 signaling. The data sets generated and analyzed during the current study are available in the Gene Expression Omnibus repository (ID: GSE64681)." @default.
• W3038798082 created "2020-07-10" @default.
• W3038798082 creator A5016626831 @default.
• W3038798082 creator A5030692575 @default.
• W3038798082 creator A5049589997 @default.
• W3038798082 creator A5053519636 @default.
• W3038798082 creator A5055280421 @default.
• W3038798082 creator A5057403192 @default.
• W3038798082 creator A5059530537 @default.
• W3038798082 creator A5074050712 @default.
• W3038798082 creator A5079309489 @default.
• W3038798082 creator A5087698754 @default.
• W3038798082 creator A5065308092 @default.
• W3038798082 date "2020-01-01" @default.
• W3038798082 modified "2023-10-18" @default.
• W3038798082 title "LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma" @default.
• W3038798082 cites W1525607149 @default.
• W3038798082 cites W1532756966 @default.
• W3038798082 cites W1566467768 @default.
• W3038798082 cites W1831046814 @default.
• W3038798082 cites W1966037423 @default.
• W3038798082 cites W1966255834 @default.
• W3038798082 cites W1975004250 @default.
• W3038798082 cites W1977530995 @default.
• W3038798082 cites W1984345184 @default.
• W3038798082 cites W1987822177 @default.
• W3038798082 cites W1988941274 @default.
• W3038798082 cites W1994404140 @default.
• W3038798082 cites W1994406452 @default.
• W3038798082 cites W2003051088 @default.
• W3038798082 cites W2005491339 @default.
• W3038798082 cites W2012176955 @default.
• W3038798082 cites W2019018578 @default.
• W3038798082 cites W2033500225 @default.
• W3038798082 cites W2034653929 @default.
• W3038798082 cites W2037961348 @default.
• W3038798082 cites W2041313145 @default.
• W3038798082 cites W2043553889 @default.
• W3038798082 cites W2045829749 @default.
• W3038798082 cites W2056031639 @default.
• W3038798082 cites W2073053682 @default.
• W3038798082 cites W2090816622 @default.
• W3038798082 cites W2100751052 @default.
• W3038798082 cites W2103648307 @default.
• W3038798082 cites W2106894326 @default.
• W3038798082 cites W2122686902 @default.
• W3038798082 cites W2122940233 @default.
• W3038798082 cites W2127538704 @default.
• W3038798082 cites W2129489850 @default.
• W3038798082 cites W2131555383 @default.
• W3038798082 cites W2142209162 @default.
• W3038798082 cites W2149696456 @default.
• W3038798082 cites W2158438223 @default.
• W3038798082 cites W2161608201 @default.
• W3038798082 cites W2169734442 @default.
• W3038798082 cites W2290711035 @default.
• W3038798082 cites W2514632341 @default.
• W3038798082 cites W2570584539 @default.
• W3038798082 cites W2738397042 @default.
• W3038798082 doi "https://doi.org/10.1016/j.jcmgh.2020.06.009" @default.
• W3038798082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7505810" @default.
• W3038798082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32615164" @default.
• W3038798082 hasPublicationYear "2020" @default.
• W3038798082 type Work @default.
• W3038798082 sameAs 3038798082 @default.
• W3038798082 citedByCount "18" @default.
• W3038798082 countsByYear W30387980822020 @default.
• W3038798082 countsByYear W30387980822021 @default.
• W3038798082 countsByYear W30387980822022 @default.
• W3038798082 countsByYear W30387980822023 @default.
• W3038798082 crossrefType "journal-article" @default.
• W3038798082 hasAuthorship W3038798082A5016626831 @default.
• W3038798082 hasAuthorship W3038798082A5030692575 @default.
• W3038798082 hasAuthorship W3038798082A5049589997 @default.
• W3038798082 hasAuthorship W3038798082A5053519636 @default.
• W3038798082 hasAuthorship W3038798082A5055280421 @default.
• W3038798082 hasAuthorship W3038798082A5057403192 @default.
• W3038798082 hasAuthorship W3038798082A5059530537 @default.
• W3038798082 hasAuthorship W3038798082A5065308092 @default.
• W3038798082 hasAuthorship W3038798082A5074050712 @default.
• W3038798082 hasAuthorship W3038798082A5079309489 @default.
• W3038798082 hasAuthorship W3038798082A5087698754 @default.
• W3038798082 hasBestOaLocation W30387980821 @default.
• W3038798082 hasConcept C104317684 @default.
• W3038798082 hasConcept C119056186 @default.
• W3038798082 hasConcept C121608353 @default.
• W3038798082 hasConcept C126322002 @default.
• W3038798082 hasConcept C173396325 @default.
• W3038798082 hasConcept C190283241 @default.
• W3038798082 hasConcept C2780210213 @default.
• W3038798082 hasConcept C2780258809 @default.
• W3038798082 hasConcept C502942594 @default.
• W3038798082 hasConcept C55493867 @default.
• W3038798082 hasConcept C57074206 @default.
• W3038798082 hasConcept C62478195 @default.
• W3038798082 hasConcept C71924100 @default.
• W3038798082 hasConcept C86803240 @default.
• W3038798082 hasConcept C95444343 @default.

• next